{"id":1195,"date":"2008-09-01T12:03:00","date_gmt":"2008-09-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/leserbrief-10"},"modified":"2022-03-17T14:11:30","modified_gmt":"2022-03-17T13:11:30","slug":"leserbrief-10","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/leserbrief-10","title":{"rendered":"Leserbrief"},"content":{"rendered":"<p>Wie relevant sind die Ergebnisse der HYVET-Studie? Prof. F.P.M. aus Gro\u00df Rodensleben schreibt: >> Eine antihypertensive Therapie ist auch bei \u00fcber Achtzigj\u00e4hrigen denkbar, aber &#8211; Priorit\u00e4ten setzen! Die Daten der HYVET-Studie (1) sprechen leider nicht so eindeutig f\u00fcr eine antihypertensive Therapie bei sehr alten Menschen mit systolischen Blutdruckwerten > 160 mmHg, wie in der Rezension [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wie relevant sind die Ergebnisse der HYVET-Studie? Prof. F.P.M. aus Gro\u00df Rodensleben schreibt: >> Eine antihypertensive Therapie ist auch bei \u00fcber Achtzigj\u00e4hrigen denkbar, aber &#8211; Priorit\u00e4ten setzen! Die Daten der HYVET-Studie (1) sprechen leider nicht so eindeutig f\u00fcr eine antihypertensive Therapie bei sehr alten Menschen mit systolischen Blutdruckwerten > 160 mmHg, wie in der Rezension [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,349,60,324,68,325,2925,2924,1646,56],"class_list":["post-1195","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-alter","tag-apoplektischer-insult","tag-blutdruck","tag-hirninfarkt","tag-hypertonie","tag-hyvet-studie","tag-indapamid","tag-perindopril","tag-schlaganfall"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1195"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1195\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}